This clinical trial is focused on studying Familial Mediterranean Fever (FMF), a genetic condition that causes recurrent episodes of fever and inflammation, often leading to pain in the abdomen, chest, or joints. The study is investigating the effectiveness of a treatment using Anakinra, a medication given as an injection, for patients who experience painful attacks despite being on long-term treatment with Colchicine, a standard medication for FMF. Some patients may not want to take daily injections, so this study looks at using Anakinra only when needed during an attack.
The purpose of the study is to evaluate how well Anakinra works in reducing the symptoms of FMF attacks in patients who are resistant to Colchicine and prefer not to have continuous daily therapy. Participants will continue their regular Colchicine treatment and will have the option to use Anakinra during an attack or when they anticipate an attack due to known triggers. The study will compare this approach to the standard care, which involves taking pain relief medications as needed along with daily Colchicine.
Throughout the study, participants will be monitored over a period of six months to assess the number of painful days they experience each month. The study will also look at the overall quality of life and any side effects, such as skin reactions at the injection site. The goal is to determine if on-demand Anakinra can provide better management of FMF symptoms compared to the current standard treatment.
France 
